Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5022 - MEK inhibitor retinopathy


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Supportive Care and Symptom Management


Tamara Shukair


Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367


T. Shukair

Author affiliations

  • Ophthalmology, hospital madrid norte sanchinarro, 28050 - Madrid/ES


Abstract 5022


To evaluate the presence and characteristics of subretinal fluid (SRF) associated with the use of MEK inhibitors in the treatment of systemic cancer MEK retinopathy is described as symmetrical bilateral disease that develops in a time-dependent and dose-dependent manner.


In this prospective, observational study, collected data from 14 patients with locally advanced or metastatic cancer undergoing treatment with the MEK inhibitor as clinical trials between 2010-2013. They underwent regular ophthalmological examinations including determination of visual function, biomicroscopy, dilated fundoscopy and optical coherence tomography (OCT).


Of the 14 participants, 10 (71%) were men; the mean (SD) age was 65 years (range, 41-80 years). Six (48%) study participants developed SRF during the study period. OCT revealed subfoveal neuroretinal elevation, serous retinal detachments often asymptomatic. In general it solves spontaneously without any apparent functional deficits or changes in structural integrity, and does not require the suspension of the treatment.


The presence of serous retinal detachment in patients undergoing treatment with the MEK inhibitor is common. Visual symptoms were mild and mainly transient and the presence of SRF did not lead to permanent ocular disorder. It is important to investigate all previous ocular disorders and pharmacologic interactions of MEK inhibitor that could associate with ocular effects.

Clinical trial identification

Legal entity responsible for the study

START Madrid




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.